|HU, HAIXIA - Southwest University|
Submitted to: International Symposium on Avian Corona and Pneumoviruses and Complicating Pathogens
Publication Type: Abstract Only
Publication Acceptance Date: 4/1/2014
Publication Date: 6/21/2014
Citation: Yu, Q., Roth, J.P., Hu, H., Estevez, C., Zsak, L. 2014. Generation and evaluation of a recombinant Newcastle disease virus (NDV) expressing the F and G proteins of avian metapneumovirus subtype C (aMPV-C) as a bivalent vaccine against NDV and aMPV-C challenges in turkeys [abstract]. In: Programme and Abstracts of the 8th International Symposium on Avian Corona- and Pneumoviruses and Complicating Pathogens. 2nd Annual Meeting of the COST Action FA1207, June 17-20, 2014. p. 92.
Technical Abstract: Virulent strains of Newcastle disease virus (NDV) and avian metapneumovirus (aMPV) can cause serious respiratory diseases in poultry. Vaccination combined with strict biosecurity practices has been the recommendation for controlling NDV and aMPV diseases in the field. Previously we generated a NDV recombinant virus expressing the glycoprotein (G) of aMPV-C as a bivalent vaccine, which provided a partial protection against aMPV-C challenge. In the present study we engineered a NDV LaSota strain-based recombinant virus using revers genetics technology to express the aMPV-C fusion (F) protein in addition to the G protein as a bivalent vaccine. This recombinant virus, rLS/aMPV-C F&G, was slightly attenuated in vivo, yet maintained similar cytopathic effects and virus titers in vitro when compared to the parental LaSota virus. Expression of the aMPV-C F/G protein in the recombinant virus-infected cells was detected by immunofluorescence assay. Vaccination of turkeys with two doses of rLS/aMPV-C F&G (prime and boost) induced aMPV-C and NDV-specific antibody responses and provided significantly improved protection against pathogenic aMPV-C challenge and complete protection against velogenic NDV CA02 strain challenge. These results suggest that the rLS/aMPV-C F&G recombinant virus is a safe and effective bivalent vaccine, and that expression of both the F and G protein of aMPV-C induced a stronger protective immunity against the aMPV disease.